330 related articles for article (PubMed ID: 37046332)
21. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
22. A review of glioblastoma immunotherapy.
Medikonda R; Dunn G; Rahman M; Fecci P; Lim M
J Neurooncol; 2021 Jan; 151(1):41-53. PubMed ID: 32253714
[TBL] [Abstract][Full Text] [Related]
23. Recent Advances in Immune Cell Therapy for Glioblastoma.
Kang X; Zheng Y; Hong W; Chen X; Li H; Huang B; Huang Z; Tang H; Geng W
Front Immunol; 2020; 11():544563. PubMed ID: 33193310
[TBL] [Abstract][Full Text] [Related]
24. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy for Neuro-Oncology.
Majd N; Dasgupta P; de Groot J
Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015
[TBL] [Abstract][Full Text] [Related]
26. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.
Yang T; Kong Z; Ma W
Hum Vaccin Immunother; 2021 Feb; 17(2):546-553. PubMed ID: 32643507
[TBL] [Abstract][Full Text] [Related]
27. The Safety of available immunotherapy for the treatment of glioblastoma.
Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
[TBL] [Abstract][Full Text] [Related]
28. Current Status and Challenges of Vaccination Therapy for Glioblastoma.
Hosseinalizadeh H; Rahmati M; Ebrahimi A; O'Connor RS
Mol Cancer Ther; 2023 Apr; 22(4):435-446. PubMed ID: 36779991
[TBL] [Abstract][Full Text] [Related]
29. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
Wang C; Yu M; Zhang W
Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
[TBL] [Abstract][Full Text] [Related]
30. The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma.
Liu X; Zhao Z; Dai W; Liao K; Sun Q; Chen D; Pan X; Feng L; Ding Y; Wei S
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686584
[TBL] [Abstract][Full Text] [Related]
31. Advances in immunotherapy for glioblastoma multiforme.
Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
Front Immunol; 2022; 13():944452. PubMed ID: 36311781
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in Glioblastoma: A Clinical Perspective.
Desbaillets N; Hottinger AF
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359621
[TBL] [Abstract][Full Text] [Related]
33. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
34. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.
Li Y; Sharma A; Maciaczyk J; Schmidt-Wolf IGH
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163235
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives.
Sener U; Ruff MW; Campian JL
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806051
[TBL] [Abstract][Full Text] [Related]
36. Natural Killer Cell-Based Immunotherapy against Glioblastoma.
Morimoto T; Nakazawa T; Maeoka R; Nakagawa I; Tsujimura T; Matsuda R
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768432
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.
Salvato I; Marchini A
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610954
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for Glioblastoma: Current Progress and Challenges.
Yu MW; Quail DF
Front Immunol; 2021; 12():676301. PubMed ID: 34054867
[TBL] [Abstract][Full Text] [Related]
39. The current and future aspects of glioblastoma: Immunotherapy a new hope?
Patel V; Shah J
Eur J Neurosci; 2021 Aug; 54(3):5120-5142. PubMed ID: 34107127
[TBL] [Abstract][Full Text] [Related]
40. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
